반응식
[C:1]([NH:22][C@H:23]([C:30]([OH:32])=[O:31])[CH2:24][O:25][P:26]([OH:29])([OH:28])=[O:27])(=[O:21])[CH2:2][CH2:3][CH2:4]/[CH:5]=[CH:6]\[CH2:7][CH:8]=[CH:9][CH2:10][CH:11]=[CH:12][CH2:13][CH:14]=[CH:15][CH2:16][CH2:17][CH2:18][CH2:19][CH3:20].[C:33](O)(=O)CCC/C=C\CC=CCC=CCC=CCC=CCC.Cl.COC(=O)[C@H]([C@@H](C)O)N>>[C:1]([NH:22][C@H:23]([C:30]([OH:32])=[O:31])[C@@H:24]([CH3:33])[O:25][P:26]([OH:29])([OH:28])=[O:27])(=[O:21])[CH2:2][CH2:3][CH2:4]/[CH:5]=[CH:6]\[CH2:7][CH:8]=[CH:9][CH2:10][CH:11]=[CH:12][CH2:13][CH:14]=[CH:15][CH2:16][CH:17]=[CH:18][CH2:19][CH3:20]참가 물질
4
실험 절차
This compound was prepared as described above for (6), using 0.5 mmol (151 mg) of cis-5,8,11,14,17-eicosapentaenoic acid and 1 mmol (170 mg) of L-threonine methyl ester hydrochloride; yield 99 mg, (41%); Rf 0.05-0.10 (system B); 1H-NMR (CD3SOCD3, 200 MHz) δ0.9-1.0 (t, 3H, ω-CH3); 1.2-1.4 (d, 3H, CH3CHOP); 1.5-1.6 (t, 2H, CH2); 2.0-2.2 (m, 6H, CH2CO and 2CH2CH═CH); 2.7-2.9 (br s, 8H, 4HC═CH—CH2—CH═CH); 4.1-4.3 (m, 2H, 2CH); 5.2-5.4 (br s, 10H, 5HC═CH); 8.2-8.4 (m, 3H, NH and 2POH)
후처리
- customThis compound was prepared
출처 및 근거
- ORD 기록
- ord-c452bef65db54635b0f57562d50b620a
- 출처 데이터셋
- uspto-grants-2002_06
- 특허 번호
- US06403554B2
연결된 노트
불러오는 중…